pharmaphorum

NOVEMBER 23, 2021

GSK gets worldwide rights to the potentially first-in-class drug, with the exception of China, and will be wholly responsible in its markets for clinical development and commercialisation. Preliminary data has shown that the drug can reduce levels of HSD17B13 protein as well as other liver enzymes that are biomarkers for NASH.

Sales 52

Sales Drugs Trials RNA 52

pharmaphorum

MAY 14, 2021

Merck KGaA had been developing the drug with partner Avillion and van Amstel’s team got in touch as soon as they heard the German pharma was considering selling it as part of a pipeline rethink. Licensed in from Ablynx in 2013 five years before a merger with Sanofi, German Merck recognised its potential.

Licensing 61

Licensing Licensing Drugs Marketing 61

Drug Discovery World

MAY 6, 2024

billion on R&D during 2021, with Germany and Switzerland being the biggest contributors, and around one fourth of clinical trials worldwide were performed in Europe 1. The city is host to many innovative biotech companies, including relative newcomers Orexa, a company that recently launched its first Phase II clinical trial.

Drugs 59

Drugs Life Science Gene Editing Gene 59

pharmaphorum

SEPTEMBER 29, 2020

As summarised by The National Institutes of Health, this includes reducing the number of redundant clinical trials, enhancing the statistical strength of studies, reducing overall costs and risks, and improving study participant recruitment, all while triggering creativity and innovation between collaborators.

Research 132

Research Gene Editing Gene Development 132

Drug Discovery World

MARCH 29, 2023

Moreover, an extra six months of RDP for drugs with full comparator clinical trials (rather than showing only that a drug is no worse than the standard of care). The draft also proposes a voucher system for antibiotic development, in which vouchers will grant one extra year of RDP, transferable to other drugs or sellable.

Clinical Trials 52

Clinical Trials Clinical Trials Production Medicine 52

Drug Discovery World

OCTOBER 4, 2022

million from the National Institute on Aging of the National Institutes of Health, the company plans to begin a Phase Ia clinical trial evaluating its lead tau self- association small molecule inhibitor OLX-07010. . Several of the large pharma companies have recently re-entered the dementia field.

Development 52

Development In-Vivo Compound Screening Clinical Development 52

pharmaphorum

SEPTEMBER 8, 2022

Big pharma has already noted its interest in the area, as seen in Novartis’ investments. Last year, the company signed two deals in quick succession, which saw it form a licensing deal worth $1.3 billion with Artios Pharma and with iTheranostics for a number of diagnostic radiopharmaceuticals.

Manufacturing 105

Manufacturing Development Drugs Antibody 105

pharmaphorum

JANUARY 29, 2021

US drugmaker Eli Lilly – still waiting for an FDA decision on one non-opioid pain drug – has just added another to its pipeline via a licensing agreement with Japan’s Asahi Kasei worth up to $410 million. Other candidates include a PACAP38 antibody, SSTR4 agonist and TRPA1 antagonist, all in phase 1 development.

Licensing 52

Licensing Licensing Bioavailability Antibody 52

Drug Discovery World

OCTOBER 16, 2023

Dr Tralau-Stewart says: “Indeed, many academic institutions have established new ways of supporting the discovery pipeline, providing tech transfer offices to support licensing, and entrepreneurship and start-up support through fundraising, accelerators, and incubators. appeared first on Drug Discovery World (DDW).

Drugs 75

Drugs Life Science Gene Therapy Genome 75

pharmaphorum

AUGUST 4, 2020

Shares in Redx Pharma were soaring this morning after it licensed its preclinical fibrotic disease drug RXC006 to AstraZeneca. The company’s shares were valued as high as 95p on the London Stock Exchange following the announcement, the highest they had been since 2015.

Drugs 98

Drugs Clinical Trials Clinical Trials Pharma Companies 98

XTalks

SEPTEMBER 5, 2023

Xtalks spoke with Maria Reyes Boceta-Muñoz, Clinical Operations Head of Development R&D at GlaxoSmithKline in Spain, Portugal & Israel, to understand the current vaccine development climate and where the sector is headed.

Vaccination 96

Vaccination Vaccine Development Clinical Trials 96

pharmaphorum

MAY 21, 2021

It builds on the company’s four partnership projects: two with the generics and biosimilars firm Hikma, one with US biotech Inhibrix and another with an unnamed biosimilars partner. Regulators may not require the large phase 3 trials needed to approve completely new drugs, as safety is proven.

Insulin 52

Insulin Drugs Production Marketing 52

Drug Discovery World

OCTOBER 7, 2022

RA: How can the integration of industry and academia help streamline drug development? . TH : Increasingly, large pharma companies need scale, agility and access to academic partnerships to succeed. It is unsurprising that many pharma companies are increasingly keen to work with academia or academic spin-out.

HR 52

HR Research Drugs Development 52

The Pharma Data

DECEMBER 16, 2020

However, its efficacy is quite a bit lower than the mRNA vaccine developed by Pfizer and BioNTech, which has a 95% efficacy, and one developed by Moderna, which has a 94% efficacy. During Phase III trials, one of the cohorts was administered one and a half doses, as opposed to two full doses. AstraZeneca’s efficacy is at 70.4%.

Vaccination 52

Vaccination Vaccine DNA Antibody 52